Kiora Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kiora Pharmaceuticals generated cash of -$9,556,951, which is more than the previous year. Cash used in financing activities reached the amount of $5,966,066 last year. Net change in cash is therefore -$3,554,865.
Cash Flow
| 2014 | -950.61K | 0 | 613.27K |
|---|---|---|---|
| 2015 | -4.45M | -20K | 12.61M |
| 2016 | -8.41M | 149.74K | 3.49M |
| 2017 | -6.46M | -36.99K | 10.67M |
| 2018 | -10.84M | -270K | 11.30M |
| 2019 | -8.15M | 0 | 3.92M |
| 2020 | -7.31M | -244.43K | 4.99M |
| 2021 | -10.88M | -157.02K | 17.79M |
| 2022 | -10.42M | 6.37K | 8.62M |
| 2023 | -9.55M | 0 | 5.96M |
KPRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 6.01M | 7.89M | 1.23M | 3.82M | 8.04M | 7.85M | 3.68M | 8.39M | 167.00K | 501.17K |
Operating activities | ||||||||||
Net income | -12.51M | -13.58M | -16.39M | -8.09M | -7.09M | -10.81M | -13.21M | -13.34M | -8.38M | -1.55M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 62.42K | 41.60K | 45.29K | 33.39K | 213.93K | 38.48K | 19.28K | 5.18K | 1.25K | 1.72K |
Stock-based compensation expense | 754.94K | 462.45K | 842.47K | 723.85K | 852.23K | 0 | 870.30K | 510.99K | 1.22M | 26.81K |
| Deferred income tax benefit | 754.94K | 462.45K | 842.47K | 723.85K | 852.23K | 0 | 870.30K | 510.99K | 1.22M | 26.81K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | -872.73K | -441.19K | -18.95K | 13.21K | -685.73K | 32.44K | 3.24M | -907.5K | 0 |
Inventories | 0 | 872.73K | 441.19K | 18.95K | -13.21K | 0 | 0 | 0 | 167.44K | 0 |
Accounts payable | -808.01K | 782.46K | -310.66K | 136.69K | 146.63K | -642.43K | -706.03K | 712.79K | -148.25K | 552.25K |
Cash generated by operating activities | -9.55M | -10.42M | -10.88M | -7.31M | -8.15M | -10.84M | -6.46M | -8.41M | -4.45M | -950.61K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20K | 0 |
Investments In Property Plant And Equipment | 1 | 0 | -63.86K | -133.79K | 0 | -270K | -36.99K | -11K | 0 | 0 |
Acquisitions Net | 0 | 6.37K | -93.15K | -110.64K | 0 | 0 | 0 | 185.74K | 0 | 0 |
Cash generated by investing activities | 0 | 6.37K | -157.02K | -244.43K | 0 | -270K | -36.99K | 149.74K | -20K | 0 |
Financing activities | ||||||||||
Common Stock Issued | 6.15M | 5.37M | 18.75M | 5M | 1.87M | 10.10M | 10.58M | 3.76M | 14.10M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -15.62K | 0 | 0 | -2.61K | 0 | 0 | 2.90M | 0 | 0 |
Repayments of term debt | 0 | 0 | -212.28K | -278.19K | 0 | -9.78K | 0 | -2.86K | 0 | 0 |
Cash used in financing activities | 5.96M | 8.62M | 17.79M | 4.99M | 3.92M | 11.30M | 10.67M | 3.49M | 12.61M | 613.27K |
Net Change In Cash | -3.55M | -1.88M | 6.66M | -2.59M | -4.22M | 198.20K | 4.17M | -4.75M | 8.22M | -334.17K |
Cash at end of period | 2.45M | 6.01M | 7.89M | 1.23M | 3.82M | 8.04M | 7.85M | 3.63M | 8.39M | 167.00K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |